Clearance given for Panretin gel.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use; D017277:Drug Approval; D005782:Gels; D006801:Humans; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D005782:Gels; D014212:Tretinoin